BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. Mol Cancer Ther 2016;15:819-29. [PMID: 26883271 DOI: 10.1158/1535-7163.MCT-15-0093] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Felker J, Broniscer A. Improving long-term survival in diffuse intrinsic pontine glioma. Expert Rev Neurother 2020;20:647-58. [PMID: 32543245 DOI: 10.1080/14737175.2020.1775584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gage MC, Thippeswamy T. Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases. CNS Drugs 2021;35:1-20. [PMID: 33515429 DOI: 10.1007/s40263-020-00787-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics 2019;12:E20. [PMID: 31878061 DOI: 10.3390/pharmaceutics12010020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
4 Ni S, Chen R, Hu K. Experimental murine models of brainstem gliomas. Drug Discov Today 2021:S1359-6446(21)00567-5. [PMID: 34954326 DOI: 10.1016/j.drudis.2021.12.016] [Reference Citation Analysis]
5 Gage M, Putra M, Wachter L, Dishman K, Gard M, Gomez-estrada C, Thippeswamy T. Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress. Antioxidants 2022;11:61. [DOI: 10.3390/antiox11010061] [Reference Citation Analysis]
6 Guntner AS, Peyrl A, Mayr L, Englinger B, Berger W, Slavc I, Buchberger W, Gojo J. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol Commun 2020;8:78. [PMID: 32493453 DOI: 10.1186/s40478-020-00953-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
7 Cooper E, Choi PJ, Denny WA, Jose J, Dragunow M, Park TI. The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. Front Oncol 2021;11:654921. [PMID: 34141613 DOI: 10.3389/fonc.2021.654921] [Reference Citation Analysis]
8 Yang RC, Qu XY, Xiao SY, Li L, Xu BJ, Fu JY, Lv YJ, Amjad N, Tan C, Kim KS, Chen HC, Wang XR. Meningitic Escherichia coli-induced upregulation of PDGF-B and ICAM-1 aggravates blood-brain barrier disruption and neuroinflammatory response. J Neuroinflammation 2019;16:101. [PMID: 31092253 DOI: 10.1186/s12974-019-1497-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
9 Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, Picard D, Burrus B, Becher OJ, Thompson EM. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. Neurosurgery 2020;86:742-51. [PMID: 31225627 DOI: 10.1093/neuros/nyz212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rathi S, Griffith JI, Zhang W, Zhang W, Oh JH, Talele S, Sarkaria JN, Elmquist WF. The influence of the blood-brain barrier in the treatment of brain tumours. J Intern Med 2022. [PMID: 35040235 DOI: 10.1111/joim.13440] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Gage M, Putra M, Gomez-Estrada C, Golden M, Wachter L, Gard M, Thippeswamy T. Differential Impact of Severity and Duration of Status Epilepticus, Medical Countermeasures, and a Disease-Modifier, Saracatinib, on Brain Regions in the Rat Diisopropylfluorophosphate Model. Front Cell Neurosci 2021;15:772868. [PMID: 34720886 DOI: 10.3389/fncel.2021.772868] [Reference Citation Analysis]
12 Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 2016;7:65696-706. [PMID: 27582545 DOI: 10.18632/oncotarget.11602] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
13 Abbassi RH, Recasens A, Indurthi DC, Johns TG, Stringer BW, Day BW, Munoz L. Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents. ACS Pharmacol Transl Sci 2019;2:402-13. [PMID: 32259073 DOI: 10.1021/acsptsci.9b00045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res 2018;35:177. [PMID: 30003344 DOI: 10.1007/s11095-018-2455-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
15 Chen YH, Cimino PJ, Luo J, Dahiya S, Gutmann DH. ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget 2016;7:23416-24. [PMID: 26981778 DOI: 10.18632/oncotarget.8030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
16 Arakaki AKS, Szulzewsky F, Gilbert MR, Gujral TS, Holland EC. Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. Neuro Oncol 2021;23:S4-S15. [PMID: 34725698 DOI: 10.1093/neuonc/noab183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest 2020;130:5313-25. [PMID: 32603316 DOI: 10.1172/JCI133310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
18 Hoeman C, Shen C, Becher OJ. CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. Front Oncol 2018;8:191. [PMID: 29904623 DOI: 10.3389/fonc.2018.00191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Power EA, Rechberger JS, Gupta S, Schwartz JD, Daniels DJ, Khatua S. Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors - An update. Adv Drug Deliv Rev 2022;185:114303. [PMID: 35460714 DOI: 10.1016/j.addr.2022.114303] [Reference Citation Analysis]
20 Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res 2018;35:31. [PMID: 29368289 DOI: 10.1007/s11095-017-2278-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
21 Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, Wang HC, Huang HR, Tsai MH. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update. Cancers (Basel) 2021;13:E195. [PMID: 33430494 DOI: 10.3390/cancers13020195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
22 Chaves C, Declèves X, Taghi M, Menet MC, Lacombe J, Varlet P, Olaciregui NG, Carcaboso AM, Cisternino S. Characterization of the Blood-Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. Pharmaceutics 2020;12:E399. [PMID: 32349240 DOI: 10.3390/pharmaceutics12050399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. Eur J Drug Metab Pharmacokinet 2017;42:915-33. [PMID: 28374336 DOI: 10.1007/s13318-017-0411-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
24 Tian S, Zhang M, Chen X, Liu Y, Lou G. MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget 2016;7:87091-9. [PMID: 27893429 DOI: 10.18632/oncotarget.13526] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
25 Wei Y, Shin MR, Sesti F. Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer's disease. Cell Death Dis 2018;9:820. [PMID: 30050035 DOI: 10.1038/s41419-018-0886-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
26 Griffith JI, Rathi S, Zhang W, Zhang W, Drewes LR, Sarkaria JN, Elmquist WF. Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. Pharmaceutics 2020;12:E1205. [PMID: 33322488 DOI: 10.3390/pharmaceutics12121205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sharma S, Carlson S, Gregory-Flores A, Hinojo-Perez A, Olson A, Thippeswamy T. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. Neurobiol Dis 2021;156:105410. [PMID: 34087381 DOI: 10.1016/j.nbd.2021.105410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Grill J, Debily M, Varlet P, Plessier A, Le Dret L, Beccaria K, Puget S, Castel D. The dark matter of diffuse intrinsic pontine gliomas: an update. Expert Opinion on Orphan Drugs 2018;7:11-20. [DOI: 10.1080/21678707.2019.1560262] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Dhar S, Gadd S, Patel P, Vaynshteyn J, Raju GP, Hashizume R, Brat DJ, Becher OJ. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. Acta Neuropathol Commun 2022;10:47. [PMID: 35395831 DOI: 10.1186/s40478-022-01336-5] [Reference Citation Analysis]
30 Vince O, Peeters S, Johanssen VA, Gray M, Smart S, Sibson NR, Stride E. Microbubbles Containing Lysolipid Enhance Ultrasound-Mediated Blood-Brain Barrier Breakdown In Vivo. Adv Healthc Mater 2021;10:e2001343. [PMID: 33191662 DOI: 10.1002/adhm.202001343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, Chang C, Gifford AJ, Tsoli M, Ziegler DS, Carcaboso AM, Becher OJ. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS One 2017;12:e0169485. [PMID: 28052119 DOI: 10.1371/journal.pone.0169485] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]